Endpoints News· @endpts · X·· 20 天前AI 评分22
AI 导读
8月daraxonrasib的里程碑式获批标志着胰腺癌治疗迈出一大步。但这也让部分等待治疗的患者在可及性上出现缺口。明天在Endpoints at ESMO活动上,胰腺癌患者Russ Reed及其妻子、倡导者Marnie将分享他们在这些缺口中的经历。欢迎参加这场及其他关于肿瘤学当下时刻的关键对话:https://events.endpoints.news/esmo2026/register?ref=twitter
正文
The landmark daraxonrasib approval in August marked a huge step forward in treatment of pancreatic cancer. But it also opened up gaps in access for some patients waiting for treatment. Tomorrow during the Endpoints at ESMO event, Russ Reed, a pancreatic cancer patient, and his wife and advocate Marnie will share their experiences with those gaps. Join us for that and other key conversations on this moment in oncology: https://events.endpoints.news/esmo2026/register?ref=twitter
来源:Endpoints News · x.com